Table 8.
Nanobody | Concentration |
U251MG |
U87MG |
NCH |
Astrocytes |
||||
---|---|---|---|---|---|---|---|---|---|
(μg/mL) | Sign. | p-value | Sign. | p-value | Sign. | p-value | Sign. | p-value | |
Nb10 | 10 | ns | ns | ns | **** | p < 0.0001 | |||
100 | ns | ns | ns | **** | p < 0.0001 | ||||
Nb79 | 100 | * | 0.0106 | ns | ns | **** | p < 0.0001 | ||
Nb179 | 100 | ** | 0.0018 | ns | ns | **** | p < 0.0001 | ||
Nb225 | 100 | ns | ns | * | 0.0151 | ns |
Data only shown for the nanobodies with significantly stronger effects than 50 μM temozolomide Significance of three samples with three replicates was calculated by one-way ANOVA.
p < 0.05, **p < 0.01, ****p < 0.0001, ns, not significant.
Sign., significance.